These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 16551136)

  • 1. Bioinformatics for cancer management in the post-genome era.
    Katoh M; Katoh M
    Technol Cancer Res Treat; 2006 Apr; 5(2):169-75. PubMed ID: 16551136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of bioinformatics in cancer epigenetics.
    Yang HH; Lee MP
    Ann N Y Acad Sci; 2004 May; 1020():67-76. PubMed ID: 15208184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canonical WNT signaling pathway and human AREG.
    Katoh Y; Katoh M
    Int J Mol Med; 2006 Jun; 17(6):1163-6. PubMed ID: 16685431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncoproteomics: state-of-the-art.
    Jain KK
    Technol Cancer Res Treat; 2002 Aug; 1(4):219-20. PubMed ID: 12625779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [OMICS and biomarkers of glial tumors].
    Idbaih A
    Rev Neurol (Paris); 2011 Oct; 167(10):691-8. PubMed ID: 21889780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapies for cancer 2004.
    Ross JS; Schenkein DP; Pietrusko R; Rolfe M; Linette GP; Stec J; Stagliano NE; Ginsburg GS; Symmans WF; Pusztai L; Hortobagyi GN
    Am J Clin Pathol; 2004 Oct; 122(4):598-609. PubMed ID: 15487459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The promise of omics-based approaches to cancer prevention.
    Meerzaman D; Dunn BK; Lee M; Chen Q; Yan C; Ross S
    Semin Oncol; 2016 Feb; 43(1):36-48. PubMed ID: 26970123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omics-based nanomedicine: the future of personalized oncology.
    Rosenblum D; Peer D
    Cancer Lett; 2014 Sep; 352(1):126-36. PubMed ID: 23941830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical bioinformatics.
    Chang PL
    Chang Gung Med J; 2005 Apr; 28(4):201-11. PubMed ID: 16013339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development.
    Yan L; Beckman R
    Biotechniques; 2005 Oct; 39(10 Suppl):S565-8. PubMed ID: 18957038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interpreting microarray data: towards the complete bioinformatics toolkit for cancer.
    Roberts ML; Kottaridis SD
    Cancer Genomics Proteomics; 2007; 4(4):301-8. PubMed ID: 17878530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioinformatics strategies for translating genome-wide expression analyses into clinically useful cancer markers.
    Rhodes DR; Chinnaiyan AM
    Ann N Y Acad Sci; 2004 May; 1020():32-40. PubMed ID: 15208181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New approaches to molecular cancer therapeutics.
    Collins I; Workman P
    Nat Chem Biol; 2006 Dec; 2(12):689-700. PubMed ID: 17108987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 'omics' of cancer.
    Geurts van Kessel A
    Cancer Genet Cytogenet; 2010 Nov; 203(1):37-42. PubMed ID: 20951317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matching cancer genomes to established cell lines for personalized oncology.
    Dudley JT; Chen R; Butte AJ
    Pac Symp Biocomput; 2011; ():243-52. PubMed ID: 21121052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor inhibition strategies in oncology.
    Harari PM
    Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the human genome in cancer with genomic approaches.
    Scheel JR; Kuo MD
    J Vasc Interv Radiol; 2006 Aug; 17(8):1225-33. PubMed ID: 16923971
    [No Abstract]   [Full Text] [Related]  

  • 19. [Molecular medicine--personalized medicine. Principles and state-of-the-art].
    Blum HE
    Dtsch Med Wochenschr; 2005 Jun; 130(25-26):1568-72. PubMed ID: 15965865
    [No Abstract]   [Full Text] [Related]  

  • 20. Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models.
    Oliveras-Ferraros C; Vazquez-Martin A; Queralt B; Adrados M; Ortiz R; Cufí S; Hernández-Yagüe X; Guardeño R; Báez L; Martin-Castillo B; Pérez-Martínez MC; Lopez-Bonet E; De Llorens R; Bernadó L; Brunet J; Menendez JA
    Int J Oncol; 2011 Dec; 39(6):1455-79. PubMed ID: 21833472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.